Jean Jacques Bienaime Sells 37,500 Shares of BioMarin Pharmaceutical (BMRN) Stock

BioMarin Pharmaceutical (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 37,500 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Tuesday, May 15th. The shares were sold at an average price of $88.75, for a total transaction of $3,328,125.00. Following the transaction, the chief executive officer now directly owns 309,350 shares of the company’s stock, valued at $27,454,812.50. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Jean Jacques Bienaime also recently made the following trade(s):

  • On Friday, May 11th, Jean Jacques Bienaime sold 18,750 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $88.42, for a total transaction of $1,657,875.00.
  • On Tuesday, April 24th, Jean Jacques Bienaime sold 20,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $82.43, for a total transaction of $1,648,600.00.
  • On Friday, April 20th, Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $83.65, for a total transaction of $836,500.00.
  • On Thursday, March 15th, Jean Jacques Bienaime sold 15,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $84.73, for a total transaction of $1,270,950.00.
  • On Thursday, February 15th, Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $84.63, for a total transaction of $846,300.00.

Shares of BMRN opened at $88.43 on Friday. BioMarin Pharmaceutical has a 52-week low of $88.57 and a 52-week high of $89.39. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.29 and a current ratio of 2.90. The firm has a market cap of $15.67 billion, a price-to-earnings ratio of -131.99 and a beta of 1.68.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Thursday, February 22nd. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.06). BioMarin Pharmaceutical had a negative return on equity of 3.01% and a negative net margin of 10.48%. The business had revenue of $358.31 million for the quarter, compared to analyst estimates of $346.24 million. analysts forecast that BioMarin Pharmaceutical will post -0.12 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Ladenburg Thalmann Financial Services Inc. boosted its stake in BioMarin Pharmaceutical by 22.9% during the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,224 shares of the biotechnology company’s stock worth $287,000 after purchasing an additional 600 shares during the last quarter. Glenmede Trust Co. NA boosted its stake in BioMarin Pharmaceutical by 3.7% during the 4th quarter. Glenmede Trust Co. NA now owns 17,520 shares of the biotechnology company’s stock worth $1,562,000 after purchasing an additional 622 shares during the last quarter. First Manhattan Co. boosted its stake in BioMarin Pharmaceutical by 104.2% during the 4th quarter. First Manhattan Co. now owns 1,225 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 625 shares during the last quarter. First Light Asset Management LLC boosted its stake in BioMarin Pharmaceutical by 2.0% during the 1st quarter. First Light Asset Management LLC now owns 31,850 shares of the biotechnology company’s stock worth $2,582,000 after purchasing an additional 637 shares during the last quarter. Finally, ETRADE Capital Management LLC boosted its stake in BioMarin Pharmaceutical by 9.5% during the 1st quarter. ETRADE Capital Management LLC now owns 7,545 shares of the biotechnology company’s stock worth $612,000 after purchasing an additional 653 shares during the last quarter.

Several equities analysts have recently weighed in on BMRN shares. BidaskClub lowered shares of BioMarin Pharmaceutical from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 24th. JPMorgan Chase cut their target price on shares of BioMarin Pharmaceutical from $131.00 to $129.00 and set an “outperform” rating for the company in a report on Wednesday, January 24th. Royal Bank of Canada reaffirmed a “hold” rating and set a $94.00 target price on shares of BioMarin Pharmaceutical in a report on Tuesday, February 27th. Credit Suisse Group reaffirmed an “outperform” rating and set a $113.00 target price on shares of BioMarin Pharmaceutical in a report on Thursday, January 18th. Finally, Morgan Stanley lifted their target price on shares of BioMarin Pharmaceutical from $112.00 to $113.00 and gave the company an “overweight” rating in a report on Monday, April 30th. Seven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $111.15.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply